WO2021251493A1 - 卵白タンパク質遺伝子における目的タンパク質をコードする遺伝子がノックインされた家禽細胞またはその製造方法 - Google Patents

卵白タンパク質遺伝子における目的タンパク質をコードする遺伝子がノックインされた家禽細胞またはその製造方法 Download PDF

Info

Publication number
WO2021251493A1
WO2021251493A1 PCT/JP2021/022359 JP2021022359W WO2021251493A1 WO 2021251493 A1 WO2021251493 A1 WO 2021251493A1 JP 2021022359 W JP2021022359 W JP 2021022359W WO 2021251493 A1 WO2021251493 A1 WO 2021251493A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
sequence
poultry
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/022359
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
勲 大石
京子 吉井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
National Institute of Advanced Industrial Science and Technology AIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Advanced Industrial Science and Technology AIST filed Critical National Institute of Advanced Industrial Science and Technology AIST
Priority to JP2022530639A priority Critical patent/JPWO2021251493A1/ja
Priority to US18/009,187 priority patent/US20230257768A1/en
Publication of WO2021251493A1 publication Critical patent/WO2021251493A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Definitions

  • the present invention relates to poultry cells knocked in in an egg white protein gene, a knock-in method, a method for producing knocked-in poultry cells, and an egg or poultry containing knocked-in poultry cells.
  • Non-Patent Documents 1 and 2 and Patent Document 1 Attempts have been made to modify the genome of poultry using genome editing technology. It has been reported that the genome editing applied to poultry uses a lentiviral vector, TALEN, and a CRISPR-Cas-based CRISPR Cas9 system (Non-Patent Documents 1 and 2 and Patent Document 1 respectively).
  • the effectors that work in the process of cutting DNA are roughly classified into "class 1" consisting of a plurality of Cass and "class 2" consisting of a single Cas.
  • class 2 CRISPR-Cas system the CRISPR-Cas9 system is widely known.
  • class 1 CRISPR-Cas system Cas3 and a cascade complex (meaning a complex of cascade and crRNA; the same applies hereinafter) and the like are known.
  • Cas3 a protein having nuclease activity and helicase activity
  • cascade and crRNA cooperate to have a function of cleaving DNA.
  • pre-crRNA which is not normally used as a component of the system.
  • Non-Patent Document 3 It has been reported that crRNA recognizes a target sequence of 32-37 bases in the CRISPR-Cas3 system (Non-Patent Document 3). On the other hand, crRNA in the CRISPR-Cas9 system recognizes the target sequence of 18-24 bases. Therefore, the CRISPR-Cas3 system can recognize the target sequence more accurately than the CRISPR-Cas9 system.
  • class 2 CRISPR systems such as the CRISPR Cas9 system have become widely used as genome editing tools, but class 1 CRISPR systems consisting of multiple Cass such as the CRISPR Cas3 system have not been developed much.
  • No. Patent Document 2 discloses that the CRISPR Cas3 system could be used to edit an endogenous DNA region in eukaryotes, but it is unclear whether the CRISPR Cas3 system functions in poultry. rice field. Further, unlike the CRISPR Cas9 system, the CRISPR Cas3 system involves a plurality of molecules. Therefore, an efficient genome editing method for poultry was unknown.
  • An object of the present invention is to provide a poultry cell knocked in, a knock-in method, a method for producing a knocked-in poultry cell, and an egg or poultry containing the knocked-in poultry cell in the egg white protein gene.
  • the present invention provides: [1] In the DNA containing the PAM sequence of CRISPR Cas3 in the egg white protein gene in which the gene encoding the target protein is knocked in and the target sequence on the 3'side of the PAM sequence, the wild-type DNA region corresponding to the PAM sequence is used. Including deletions, substitutions or insertions in comparison
  • Item 2 Item 2.
  • the poultry cell according to Item 1 wherein the DNA containing the PAM sequence of CRISPR Cas3 and the target sequence on the 3'side of the PAM sequence is 33-43 bases.
  • Item 2 The poultry cell according to Item 2, wherein the DNA containing the PAM sequence of CRISPR Cas3 and the target sequence on the 3'side of the PAM sequence is 35 bases.
  • Item 3. The poultry cell according to Item 4, wherein the DNA containing the PAM sequence of CRISPR Cas3 and the target sequence on the 3'side of the PAM sequence is the polynucleotide represented by SEQ ID NO: 2.
  • a method in which the egg white protein gene is selected from the group consisting of ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor and lysozyme.
  • the crRNA targeting the egg white protein gene comprises a polynucleotide selected from the group consisting of the polynucleotides set forth in SEQ ID NO: 9-16.
  • Item 10 The method of Item 10 or 11, wherein the donor construct does not have at least one polynucleotide selected from the group consisting of the polynucleotides set forth in SEQ ID NO: 1-8.
  • a method in which the egg white protein gene is selected from the group consisting of ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor and lysozyme.
  • the crRNA targeting the egg white protein gene is selected from the group consisting of the polynucleotides set forth in SEQ ID NO: 9-16, or the crRNA expressing nucleotide is selected from the group consisting of the polynucleotides set forth in SEQ ID NO: 1-8.
  • Item 13 The method of Item 13 or 14, wherein the donor construct does not have at least one polynucleotide selected from the group consisting of the polynucleotides set forth in SEQ ID NO: 1-8.
  • a poultry cell knocked in a knock-in method, a method for producing a knocked-in poultry cell, and an egg or poultry containing the knocked-in poultry cell in the egg white protein gene.
  • FIG. 1 shows the design of the CRISPR Cas3 target sequence.
  • Cas3 Tg1 is represented by SEQ ID NO: 1;
  • Cas3 Tg2 is represented by SEQ ID NO: 2;
  • Cas3 Tg3 is represented by SEQ ID NO: 3;
  • Cas3 Tg4 is represented by SEQ ID NO: 4;
  • Cas3 Tg5 is represented by SEQ ID NO: 5;
  • Cas3 Tg6 is represented by SEQ ID NO: 6;
  • Cas3 Tg7 is represented by SEQ ID NO: 7;
  • Cas3 Tg8 is represented by SEQ ID NO: 8.
  • FIG. 2 shows the design of the CRISPR Cas3 donor vector.
  • the upper part of FIG. 2 shows a schematic diagram of exons and introns of the ovalbumin gene and insertion sites of foreign genes.
  • SEQ ID NO: 82 is part of exon 2.
  • FIG. 2 shows a schematic diagram of a donor vector used when constructing a human GM-CSF heteroknock-in chicken by the CRISPR / Cas9 method.
  • the lower part of FIG. 2 shows a schematic diagram of a donor vector used when constructing a human GM-CSF knock-in chicken by the CRISPR / Cas3 method.
  • FIG. 3 shows the results of gene knock-in into primordial germ cell genomic DNA after neomycin selection.
  • the upper schematic diagram shows an ovalbumin gene schematic diagram (upper row), a CRISPR / Cas3 method donor vector schematic diagram (middle row), and a knocked-in schematic diagram (lower row) in order from the top.
  • Triangular P1-P3 schematically represent primers.
  • the results of the lower electrophoresis show a photograph of the genome of CRISPR / Cas3 / donor vector-introduced cells selected by neomycin, PCR amplified by P1 / P2 and electrophoresed.
  • the graph at the bottom shows the results of quantitative PCR.
  • FIG. 4 shows the results of gene knock-in into primordial germ cell genomic DNA after repeated selection of neomycin.
  • the upper schematic diagram shows an ovalbumin gene schematic diagram (upper row), a CRISPR / Cas3 method donor vector schematic diagram (middle row), and a knocked-in schematic diagram (lower row) in order from the top.
  • Triangular P1-P3 schematically represent primers.
  • the results of the lower electrophoresis show a photograph of the genome of CRISPR / Cas3 / donor vector-introduced cells selected by neomycin, PCR amplified by P1 / P2 and electrophoresed.
  • the graph at the bottom shows the results of quantitative PCR.
  • the present invention relates to a DNA in which a gene encoding a target protein is knocked in in an egg white protein gene and contains a PAM sequence of CRISPR Cas3 in the egg white protein gene and a target sequence on the 3'side of the PAM sequence. , Containing deletions, substitutions or insertions compared to the corresponding wild DNA region,
  • the egg white protein gene relates to poultry cells selected from the group consisting of ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor and lysozyme.
  • the present invention is a method of knocking in a gene encoding a target protein into an egg white protein gene.
  • the egg white protein gene is selected from the group consisting of ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor and lysozyme.
  • the present invention is a method for producing a poultry cell in which a gene encoding a target protein in an egg white protein gene is knocked in.
  • the egg white protein gene is selected from the group consisting of ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor and lysozyme.
  • polynucleotide is intended as a polymer of nucleotides and is used synonymously with the terms “gene”, “nucleic acid” or “nucleic acid molecule”.
  • Polynucleotides can be present in the form of DNA (eg, cDNA or genomic DNA) or in the form of RNA (eg, mRNA).
  • RNA eg, mRNA
  • protein is used synonymously with “peptide” or "polypeptide”.
  • knock-in may occur homozygously or heterozygously in the chromosome. Therefore, the expression of the knocked-in target gene or the amount of protein derived from the target gene is reduced or lost as compared with the wild type. When knocked in, the expression of the target gene or the amount of protein derived from the target gene is increased as compared with the wild type.
  • the "knocked-in" egg is an egg laid by a female poultry whose genotype of the knocked-in target gene is hetero (+/-), or the genotype of the knocked-in target gene is homozygous. +/+) Includes both fertilized poultry eggs. Compared to eggs laid by female poultry with a heterozygous (+/-) genotype for the knocked-in target gene, female poultry with a homozygous (+/+) genotype for the knocked-in target gene laid. Eggs contain more expression or products of the target gene.
  • the method of the present invention may target cells having a modification.
  • the cells, eggs, or poultry obtained by the method of the present invention may be further modified.
  • the modification is genome editing.
  • Genome editing is a technique for genetic modification using the error of double-stranded DNA cleavage and its repair, and is a nuclease capable of cleaving the target double-stranded DNA, and a DNA recognition component bound or complexed with the nuclease.
  • Examples of genome editing include ZFN (zinc finger nucleose), TALEN, and CRISPR.
  • ZFN zinc finger nucleose
  • TALEN Zinc finger nucleose
  • CRISPR CRISPR
  • RNA gRNA, DNA recognition component
  • the nuclease used for genome editing may have nuclease activity, and DNA polymerase, recombinase, or the like can be used in addition to the nuclease.
  • poultry examples include chickens, quails, schimen butterflies, ducks, geese, onagadori, bantams, pigeons, ostriches, pheasants, guinea fowls, and the like, preferably chickens and quails.
  • the primordial germ cells can be either male or female.
  • Poultry primordial germ cells such as chickens are floating cells and are cultured in the presence of feeder cells such as BRL cells and STO cells. Alternatively, it may be cultured in the absence of feeder cells by adding an appropriate cytokine to the medium.
  • the target gene modified by the genome editing of the present invention is not particularly limited, but is preferably an egg white protein gene.
  • the egg white protein gene refers to a gene under the control of an egg white protein expression promoter, and specific examples thereof include ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor, and lysozyme.
  • target gene is a polynucleotide encoding a protein to be expressed (referred to as "target protein"). Therefore, the target gene can be an exogenous gene or an endogenous gene, and a polynucleotide encoding a desired protein can be appropriately selected.
  • the polynucleotide can be obtained by using a known technique such as PCR or a chemical synthesis method based on the base sequence information.
  • various secretory proteins and peptides can be considered, and an antibody (monochromic antibody) or a fragment thereof (for example, scFv, Fab, Fab', F (ab') 2, Fv, single-chain antibody, scFv, dsFv, etc.), enzymes, hormones, growth factors, cytokines (eg, GM-CSF or core region), interferons, collagen, extracellular matrix molecules, functional polypeptides such as vaccines, agonistic Examples include proteins, antagonistic proteins or portions thereof.
  • the protein encoded by the target gene is, for example, a mammalian-derived, preferably human-derived, in the case of a bioactive protein that can be a drug to be administered to humans.
  • the protein encoded by the target gene is derived from any organism including microorganisms (bacteria, yeast, etc.), plants, and animals in the case of industrially usable proteins such as protein A and proteins constituting spider silk. Protein, or artificial protein or parts thereof.
  • the target gene may be a single gene or multiple genes. In the case of multiple genes, it is sufficient that the multiple genes can be expressed under the control of the egg white protein gene, and the multiple genes are expressed via a sequence such as IRES or a sequence encoding a 2A peptide. Multiple proteins may be expressed at once under the control of the ovoalbumin promoter and expressed in the form of cleavage of the peptide.
  • the protein of interest it may be designed to add an appropriate signal peptide (eg, chicken ovotransferrin signal peptide) or to add an addition sequence (eg, polyA sequence) to the 3'end. , Or the codon usage may be modified to facilitate expression in poultry.
  • the expression product of the target gene is predominantly expressed in concentrated egg white.
  • “dominant” means that (a) the expression level of the target gene in the concentrated egg white is 50% or more, 60% or more, 65% or more, 70% with respect to the expression level of the foreign gene in the entire knock-in egg by mass. It means that it is 75% or more, 80% or more, 85% or more, 90% or more, 95% or more or 98% or more, or (a) the expression level of the target gene in eggs other than thick egg white.
  • the relative concentration of the expression level of the target gene in the concentrated egg white is 1.1 times or more, preferably 2 times or more, more preferably 10 times or more.
  • the expression product of the knocked-in target gene is concentrated in the concentrated egg white, purification is easy.
  • the expression product of the target gene can be expressed in the active form. Thick egg white may become cloudy due to the expression product of the target gene, but the cloudy protein can be easily solubilized by ultrasonic treatment, addition of a solubilizer such as arginine hydrochloride, or the like.
  • the expression product of the knock-in gene expressed in the concentrated egg white may be in a dissolved state or may be in a non-dissolved state.
  • the expression product of the insoluble knock-in gene can be purified as an active protein. It is desirable to solubilize and purify the expression product of the knock-in gene.
  • ordinary purification means such as columns and dialysis are used.
  • genome editing include zinc finger, TALEN, CRISPR and the like, with TALEN and CRISPR being preferred, and CRISPR being more preferred. Genome editing methods have been developed one after another, and are not limited to these, and all genome editing methods developed in the future can be used in the present invention.
  • the drug resistance gene When knocking in by genome editing, it is preferable to stably integrate the drug resistance gene into the genome together with a useful target gene and select the knocked-in primordial germ cells.
  • the drug resistance gene include a neomycin resistance gene (Neor), a hyglomycin resistance gene (Hygr), a puromycin resistance gene (Puror), a blastsidin resistance gene (blastr), a zeosin resistance gene (Zeor), and the like.
  • a resistance gene (Neor) or a puromycin resistance gene (Puror) is preferable. It was
  • the target gene may be introduced into a primordial germ cell as a single-stranded or double-stranded nucleic acid, and in the case of a double-stranded nucleic acid, it may be introduced in the form of a plasmid vector, a BAC (bacterial artificial chromosome) vector, or the like. ..
  • the gene sequence around the translation start point of the egg white protein gene may be inserted immediately before the translation start point of the target gene.
  • the target gene When the target gene is knocked in to the locus of the egg white protein to obtain this chicken individual and an egg is obtained, it is desirable to collect the egg white of the egg in order to recover the target gene product. In order to recover more efficiently, it is desirable to recover the region containing thick egg white around the yolk.
  • genetically modified poultry can be produced from genetically modified poultry primordial germ cells obtained by the gene modification method of the present invention according to a conventional method.
  • eggs can be obtained from further genetically modified poultry. The specific procedure is shown below.
  • the recipient's endogenous primordial germ cells may be inactivated in advance by a drug or ionizing radiation before transplantation, or the number may be reduced.
  • Incubate the transplanted embryo according to the conventional method and incubate the transplanted individual.
  • the transplanting and hatching operations may be a system culture including a change in the eggshell, or a window opening method in which the eggshell is not changed.
  • the hatched individual can be sexually matured as a living body (chimeric individual) by normal breeding.
  • poultry with genetic modification derived from transplanted cells can be produced as a progeny.
  • the genome-edited primordial germ cells obtained in the present invention have high proliferative capacity, resulting in a large number of fertile sperm or eggs in chimeric individuals.
  • the frequency of gene modification contained in the gamete genome is investigated, the contribution rate of transplanted cells is evaluated, and then a mating test is conducted, or the feather color of the progeny is used for judgment. You may.
  • a homozygous genetically modified poultry By mating a female chimeric poultry transplanted with a genetically modified female primordial germ cell and a male chimeric poultry transplanted with a male primordial germ cell, a homozygous genetically modified poultry can be obtained.
  • a technology such as differentiating primordial germ cells into germ cells is developed in vitro in the future, not limited to individual poultry, genetically modified poultry will be produced by artificial insemination or microinsemination using this technology. can do.
  • genome editing involves infecting early embryos with various viral vectors or injecting plasmid vectors into early embryonic blood as a liposome complex, without going through primordial germ cell culture.
  • Endogenous primordial germ cells may be genetically engineered to establish chimeric individuals and recombinant progeny.
  • the primordial germ cells obtained by genome editing may be useful in this embodiment as well because they have high gene modification efficiency and may have sufficiently high fertility to obtain recombinant progeny and gene-modified progeny of poultry.
  • genetic modification of (intrinsic) primordial germ cells is possible without culturing the primordial germ cells.
  • the viral vector used for gene manipulation by genome editing examples include a retrovirus vector, an adenovirus vector, an adeno-associated virus vector, and a lentiviral vector. These viral vectors can be used for genome editing of cultured primordial germ cells or endogenous primordial germ cells. For example, in order to modify endogenous primordial germ cells using genome editing, a viral vector expressing a nuclease or sgRNA that recognizes and cleaves an arbitrary target sequence using a viral vector for genome editing sold by each company. Is constructed into a form that can be infectious by packaging, and genome editing in primordial germ cells is performed by administering it to the primordial germ cells such as the vesicle lobe of early poultry embryos, blood and germ cell regions, and to later generations.
  • virus vectors for genome editing are sold by many domestic and overseas companies.
  • Examples include System Biosciences using vectors, and LLC's "Lentival CRISPR / Cas9 System”.
  • a viral vector necessary for genome editing a viral vector containing the knock-in gene, a plasmid, a Bac vector, a single-stranded or double-stranded DNA, or the like can be used in combination.
  • genome editing plasmids and donor constructs that do not use or use viral vectors are made permeable to cell membranes such as liposome complexes, and primordial germ cells such as the vesicles of early poultry embryos, blood, and germ cells. It is possible to edit the genome in primordial germ cells by administering to the place where the gene is present, and to obtain a genetically modified individual or a genetically modified product in the progeny.
  • the poultry egg from the knock-in cell of the present invention obtained by the above method can stably and highly express the expression product of the target gene in the egg.
  • the stable and high expression of the expression product of the target gene in the egg means that the protein encoded by the target gene of about 1 mg or more per egg is expressed even from different individuals.
  • a form expressing a target protein of about 10 mg or more per egg, more preferably about 100 mg or more per egg can be mentioned.
  • the expression of the target gene product (protein) observed in the egg of the knock-in hen has a concentration of 5 mg / ml in the concentrated egg white, which is a conventional knock-in.
  • the concentration is much higher than that of random gene introduction that does not depend on the gene, and since the insertion position of the target gene is uniform, the variation in expression between individuals or in the same individual is small.
  • the technique of knocking in to the translation start point of the gene actually expressed in the chicken individual is used, the expression does not decrease due to the influence of silencing or the like after the G2 generation.
  • the target gene When the target gene is knocked in at the locus of the egg white protein gene by this method, the distribution of the target gene product (protein) observed in the eggs of the knock-in hen may be higher in the concentrated egg white than in the water-soluble egg white. .. Therefore, the target gene product can be efficiently recovered by recovering the region containing the thick egg white.
  • chickens knocked in by targeting the egg white allergen gene are bred, and eggs can be obtained to obtain eggs lacking or reduced in egg white allergen protein. Such eggs are expected to be hypoallergenic.
  • the poultry eggs from the knock-in cells of the present invention are produced by knock-in poultry individuals in which the same target gene is inserted in the same place throughout the body, and the difference in protein expression level among the individuals is small, and the protein expression level differs between individuals. It may be possible to correctly propagate genetic information and traits. Furthermore, by setting the position of the gene knock-in to the egg white protein gene, the main expression of the target gene can be localized to the egg white. Therefore, it is clearly less likely to affect the developmental process and chicken health than when expressed systemically, and may be superior. In addition, expressing the target gene under the control of a gene that is highly expressed in egg white, such as ovalbumin, increases the expression efficiency of the target gene, which is further preferable.
  • knock-in chickens can be efficiently established by performing gene knock-in by genome editing, but the target gene may be expressed in egg white using the CRISPR Cas3 system, or the target gene may be expressed in egg white. Products may accumulate.
  • the CRISPR Cas3 system by using the CRISPR Cas3 system, a large amount of the target gene-derived product can be present in the thick egg white in the egg white.
  • the target gene-derived product is efficiently recovered by recovering the region containing the concentrated egg white of the egg containing the target gene product, and in the preferred embodiment, the egg in which the target gene is knocked in at the locus of the egg white gene. be able to.
  • the use of the CRISPR-Cas3 system can reduce the off-target effect of introducing unintended mutations by accurately cleaving the target sequence. By reducing the off-target effect, the efficiency of knocking in the target sequence may be increased, or the efficiency of obtaining a recombinant having no unintended sequence may be increased.
  • the CRISPR-Cas3 system can be used to efficiently obtain knockin chickens that produce the protein of interest in egg white, or unintended mutations can result in knockin chickens that are impaired in developmental form or health. The sex can be lowered.
  • the CRISPR Cas3 system is; (I) Proteins with nuclease activity and helicase activity, (Ii) Cascade Complex, and (iii) crRNA, Have the function of cooperating to recognize the target sequence and cleave the DNA.
  • proteins with nuclease activity and helicase activity contain Cas3, and cascade complexes contain Cas5, 6, 7, 8 and 11.
  • Cas protein groups (Cas 3, 5, 6, 7, 8 and 11) are introduced into cells independently or at the same time as any of them, either as a protein or as a polynucleotide encoding the protein. can.
  • Those skilled in the art can appropriately adjust the concentration, amount, ratio, etc. of the Cas protein group so that they can function in the cells into which the Cas protein group has been introduced.
  • a nuclear localization signal may be added to the Cas protein group.
  • the nuclear translocation signal can be added to the N-terminal and / or C-terminal side of the Cas protein group (5'-terminal side and / or 3'-terminal side of the polynucleotide encoding each Cas protein group).
  • the addition of a nuclear localization signal can promote the localization of Cas proteins to the nucleus in cells and improve the efficiency of genome editing.
  • the nuclear localization signal may be any as long as it can translocate the protein into the nucleus, and a person skilled in the art can use any nuclear localization signal as appropriate.
  • nuclear localization signal examples include, for example, PKKKRKV (SEQ ID NO: 53) (single node type SV40), PAAKRRVKLD (SEQ ID NO: 54) (c-myc), PQPKKKP (SEQ ID NO: 55) (p53), KRPAATKKA GQAKKK (SEQ ID NO: 56).
  • Nucleoplasmin KRTADGSEFESSKKRKVE (SEQ ID NO: 57) (binode type SV40), preferably PKKKRKV (SEQ ID NO: 53) or KRTADGSEFESPKKRKVE (SEQ ID NO: 57), but not limited to these.
  • the CRISPR-Cas3 system PAM sequences are, for example, "AAG”, “AGG”, “GAG”, “TAC”, “ATG”, and “TAG”.
  • the PAM sequence is preferably "AAG”.
  • the target sequence is a sequence of 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 bases adjacent to the 3'side of the PAM sequence, and is a sequence of 32-37 bases, more preferably. Is 32 bases. Therefore, the DNA containing the PAM sequence (3 bases) of CRISPR Cas3 and the target sequence on the 3'side of the PAM sequence is 33-43 bases, preferably 35-40 bases.
  • the DNA containing the PAM sequence (3 bases) of CRISPR Cas3 and the target sequence on the 3'side of the PAM sequence is preferably 35 bases.
  • the DNA containing the target sequence on the 3'side of the PAM sequence of CRISPR Cas3 may also contain deletions, substitutions or insertions of 1, 2, 3, or 4 bases as compared to the wild-type sequence. It is intended that it can be targeted by the system.
  • target sequence (including PAM sequence) used in the present invention is that the target sequence is described below; Tg1: 5'-agacaccaccacacacaAataaataagagtgagc-3'(SEQ ID NO: 1), Tg2: 5'-aggtgagcctacagttataagattaaaacctttgtcc-3'(SEQ ID NO: 2), Tg3: 5'-agattaaaacctttgccctgctcatggagccac-3'(SEQ ID NO: 3), Tg4: 5'-agtgtggccaccccaactccccagagtgttaccc-3'(SEQ ID NO: 4), Tg5: 5'-aagctcaggtagagaaattctccctctctctctctctctctctctc-3'(SEQ ID NO: 5), Tg6: 5'-aagcaaaata
  • the CRISPR-Cas3 system can specifically recognize the target sequence and cleave the target sequence by using crRNA.
  • crRNA of the present invention it is particularly preferable to use a pre-crRNA.
  • the precrRNA used in the present invention typically has a structure of "leader sequence-repeat sequence-spacer sequence-repeat sequence (LRSR structure)" or “repeat sequence-spacer sequence-repeat sequence (RSR structure)".
  • the leader sequence is an AT-rich sequence and functions as a promoter for expressing precrRNA.
  • the repeat sequence is a sequence that repeats via the spacer sequence, and the spacer sequence is a sequence designed in the present invention as a sequence complementary to the target DNA (originally, a foreign substance incorporated in the process of adaptation).
  • the pre-crRNA becomes a mature crRNA when cleaved by the proteins that make up the cascade (eg, Cas6 for types I-A, B, DE, Cas5 for type I-C).
  • the chain length of the leader sequence is 86 bases and the chain length of the repeat sequence is 29 bases.
  • the chain length of the spacer sequence is, for example, 10-60 bases, preferably 20-50 bases, more preferably 25-40 bases, typically 32-37 bases. Therefore, in the case of the LRSR structure, the chain length of the precrRNA used in the present invention is, for example, 154-204 bases, preferably 164-194 bases, more preferably 169-184 bases, typically 176-181 bases. Is.
  • the RSR structure for example, it is 68-118 bases, preferably 78-108 bases, more preferably 83-98 bases, and typically 90-95 bases.
  • the process by which the repeat sequence of precrRNA is cleaved by the proteins constituting the cascade is considered to be important. Therefore, it should be understood that the repeat sequence may be shorter or longer than the chain length as long as such cleavage occurs. That is, the pre-crRNA can be said to be a crRNA in which a sequence sufficient for cleavage by the proteins constituting the cascade is added to both ends of the mature crRNA described later.
  • a preferred embodiment of the method of the invention thus comprises the step of introducing the CRISPR-Cas3 system into eukaryotic cells and then cleaving crRNA by the proteins constituting the cascade.
  • the mature crRNA produced by cleaving the pre-crRNA has a structure of "5'handle sequence-spacer sequence-3'handle sequence".
  • the 5'handle sequence consists of 8 bases at positions 22-29 of the repeat sequence and is held in Cas5.
  • the 3'handle sequence consists of 21 bases at positions 1-21 of the repeat sequence, forming a stem-loop structure at positions 6-21 and held by Cas6. Therefore, the chain length of mature crRNA is usually 61-66 bases.
  • RNA sequence may be appropriately designed according to the target sequence for which DNA editing is desired.
  • RNA synthesis can be performed using any method known in the art.
  • crRNA used in the present invention is: 5'-aagacacccaggacacaAauaaaaggugagc-3'(SEQ ID NO: 9), 5'-agagugagccuacaguaguaaagaauuaaaaccuugc-3'(SEQ ID NO: 10), 5'-aagaauaaaccuuuuugccucuccaauggagccac-3'(SEQ ID NO: 11), 5'-aagugugccacccuccaacucccagaguguuccc-3'(SEQ ID NO: 12), 5'-aagcucadguacagaaaauauucaccuccucucuc-3'(SEQ ID NO: 13), 5'-aagcaaaaaucagcaugaugaagcaaucucuucuagcu-3'(SEQ ID NO: 14), 5'-aagcaaucucuauagcuuccaagccccucucucugau-3'
  • a polynucleotide expressing a polynucleotide containing crRNA may be used.
  • the crRNA-expressing polynucleotide may be provided by incorporating it into a vector.
  • Cas protein group used in the present invention is as follows; Cas3; a protein encoded by a polynucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 17.
  • Cas5 a protein encoded by a polynucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 18.
  • Cas6 a protein encoded by a polynucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 19.
  • Cas7 a protein encoded by a polynucleotide consisting of the nucleotide sequence shown in SEQ ID NO: 20.
  • Cas8 a protein encoded by a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 21 and Cas11; a protein encoded by a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 22. Is.
  • Cas protein group used in the present invention is as follows; Cas3; a protein consisting of the amino acid sequence set forth in SEQ ID NO: 23, Cas5; a protein consisting of the amino acid sequence set forth in SEQ ID NO: 24, Cas6; a protein consisting of the amino acid sequence set forth in SEQ ID NO: 25, Cas7; a protein consisting of the amino acid sequence set forth in SEQ ID NO: 26, Cas8; a protein consisting of the amino acid sequence represented by SEQ ID NO: 27 and Cas11; a protein consisting of the amino acid sequence represented by SEQ ID NO: 28, Is.
  • the polynucleotide encoding the wild-type protein constituting the CRISPR Cas3 system includes a polynucleotide modified for efficient expression in eukaryotic cells. That is, a polynucleotide encoding a Cas protein group and having been modified can be used.
  • a polynucleotide modification is a modification to a base sequence suitable for expression in eukaryotic cells, for example, codons can be optimized for expression in eukaryotic cells.
  • a sequence having 70%, 80%, 90%, 95%, 99%, or more sequence identity with the sequence shown in the present invention may have the same function as the sequence shown by SEQ ID NO:. good.
  • a Cas3 protein based on a sequence encoding Cas3 having 90% sequence identity with the sequence set forth in SEQ ID NO: 17 still has nuclease activity and helicase activity.
  • the PAM sequence of CRISPR Cas3 in the egg white protein gene and the target sequence on the 3'side of the PAM sequence are included.
  • DNA may have deletions, substitutions or insertions compared to the corresponding wild DNA region.
  • the deletion, substitution, or insertion may be derived from the donor construct in the step of introduction into poultry cells.
  • the donor construct can include an HR template in a homologous recombination (HR) repair mechanism and may optionally be incorporated into the vector.
  • Homologous recombination repair is an intracellular mechanism for repairing single-stranded DNA and double-stranded DNA damage.
  • the HR template can include a polynucleotide encoding the gene of interest or an adjacent sequence that provides homology to the DNA flanking the endogenous gene to be replaced.
  • the flanking sequences include upstream and / or downstream sequences of endogenous genes.
  • the flanking sequences include upstream and downstream sequences of the endogenous gene.
  • the adjacent sequences are not particularly limited, but are any number between about 250, 500, 750, 1000, 1500, 2000, 2500, 2500, 3000, 3500, 4000, 5000, 6000, 7000, 8000, 9000 and 10000, respectively. Can be the base of.
  • the flanking sequence in the HR template can include any deletion, substitution or insertion provided that the homologous recombination repair mechanism works.
  • the donor construct optionally contains a drug resistance gene.
  • the drug resistance gene include a neomycin resistance gene (Neor), a hyglomycin resistance gene (Hygr), a puromycin resistance gene (Puror), a blastsidin resistance gene (blastr), a zeosin resistance gene (Zeor), and the like.
  • a resistance gene (Neor) or a puromycin resistance gene (Puror) is preferable.
  • the donor construct contains upstream DNA of the endogenous gene, a polynucleotide of interest gene and downstream DNA of the endogenous gene in the order of 5'to 3'.
  • the donor construct optionally contains a marker.
  • the marker include those that visualize knocked-in cells such as a fluorescent protein gene, and include, but are not limited to, EGFP, mCherry, dsRed, and the like.
  • the PAM sequence and the target sequence on the 3'side of the PAM sequence are recognized, and the DNA around the target sequence (which may include the target sequence itself) is largely scraped, so that it is used when knocking in.
  • the donor construct does not have a specific "PAM sequence and a target sequence on the 3'side of the PAM sequence".
  • the donor construct itself is also greatly scraped to have various unexpected shapes, or the knocked-in DNA is again CRISPR Cas3. It becomes difficult to obtain the expected knock-in cells because they are recognized by the system and are greatly scraped.
  • the donor construct does not have at least one polynucleotide selected from the group consisting of the polynucleotides set forth in SEQ ID NO: 1-8.
  • the absence of "PAM sequence and target sequence on the 3'side of the PAM sequence” corresponds to "PAM sequence of Cas3 and DNA containing the target sequence on the 3'side of the PAM sequence".
  • Not having "the PAM sequence and the target sequence on the 3'side of the PAM sequence” may be any aspect that is not recognized by the CRISPR Cas3 system, and the PAM sequence of Cas3 and the target sequence on the 3'side of the PAM sequence may be used.
  • the DNA it contains it contains deletions, substitutions or insertions or combinations thereof as compared to the corresponding wild DNA region. If the PAM sequence is mutated, for example, aag is replaced with ttt.
  • the "PAM sequence and the target sequence on the 3'side of the PAM sequence" are not provided, 1, 2, 3, 4, 5, 6, 7, 8 are compared with the corresponding wild-type DNA region. , 9, 10, 15, 20, 25, 30, 35, or 40 or more bases different.
  • the insertion may disrupt the PAM sequence of Cas3 and the DNA containing the target sequence on the 3'side of the PAM sequence. Deletions or substitutions may result in the loss of the PAM sequence of Cas3 and the DNA containing the target sequence on the 3'side of the PAM sequence.
  • a cell containing a sequence having no "PAM sequence and a target sequence on the 3'side of the PAM sequence” is used in the HR template in the DNA containing the "PAM sequence of Cas3 and the target sequence on the 3'side of the PAM sequence". This can be achieved by preparing DNA that "contains deletions, substitutions or insertions as compared to the corresponding wild DNA region" and used in the knock-in step.
  • the kit used in the CRISPR-Cas3 system of the present invention A kit for knocking in a gene encoding a target protein in an egg white protein gene.
  • the egg white protein gene is selected from the group consisting of ovalbumin, ovomucoid, ovomucin, ovotransferrin, ovoinhibitor and lysozyme.
  • the components of the kit of the present invention may be in a mode in which all or part of them are mixed, or in a mode in which each is independent. Other components of the kit of the present invention can be appropriately selected by those skilled in the art.
  • the kit may contain various configurations for editing the DNA of poultry cells.
  • the components of the kit may be those that can edit the DNA of poultry cells.
  • the kit of the present invention may further include instructions for use.
  • CRISPR Cas3 is a new genome editing technology, and it was necessary to develop a new method in order to express a large amount of foreign genes in egg white using this technology.
  • the target sequence and the DNA cleavage site are far apart, so it was considered necessary to select an appropriate target site in order to efficiently knock in a foreign gene in the vicinity of exon 2, especially near the translation start point.
  • a polynucleotide having the following series of complementary sequences was obtained from Eurofins Genomics as a polynucleotide having a base sequence for expressing a crRNA targeting each target sequence; SEQ ID NO: 37 and 38 corresponding to Tg1, SEQ ID NO: 39 and SEQ ID NO: 40 corresponding to Tg2, SEQ ID NO: 41 and SEQ ID NO: 42 corresponding to Tg3, and SEQ ID NO: 43 and SEQ ID NO: 44, Tg5 corresponding to Tg4.
  • the donor vector is arranged in the order of 5'to 3', (i) a 5'homologous region upstream of 2.8 kb from the ovalbumin translation start point, and (ii) an ovalbumin translation start point. It was constructed to contain an in-frame foreign gene, (iii) a drug resistance gene, and (iv) a 3 kb 3'homologous region containing 7 bases downstream from the ovalbumin translation initiation site.
  • the foreign gene of (ii) was designed to link the human GM-CSF core region to the 3'end of the chicken ovotransferrin signal peptide and add the polyA sequence derived from the bovine growth hormone gene (SEQ ID NO: 35).
  • the sequence of the insert portion of the donor vector in which (i) to (iv) are linked is shown in SEQ ID NO: 36. This was inserted between pBluescriptII (Clontech) SalI-BamHI (pBS-OVA5-hGMCSF-neo-OVA3), and the following donor vector was constructed based on this. Eight donor vectors (pBS-Donor1-Donor8) were constructed in which the PAM sequence (AAG) corresponding to Tg1-Tg8 was replaced with TTT so that the 3'homologous region was not recognized by the CRISPR Cas3 system.
  • a primer set containing the expected mutation using pBS-OVA5-hGMCSF-neo-OVA3 as a template was obtained (Eurofin Genomics), and site-specific mutation was introduced by PCR.
  • the polynucleotide sequences of the primers used were Donor1 (SEQ ID NO: 58 and SEQ ID NO: 59), Donor2 (SEQ ID NO: 60 and SEQ ID NO: 61), Donor3 (SEQ ID NO: 62 and SEQ ID NO: 63), Donor4 (SEQ ID NO: 64 and SEQ ID NO: 61).
  • Patent Document 1 1.8 ⁇ g of 1 ⁇ 10 5 to 5 ⁇ 10 5 chicken primordial germ cells collected from 2.5-day embryonic blood of white reghon (high-line species) and cultured.
  • pPB-CAG-hCas3, 0.6 ⁇ g pCAG-all-in-one-hCascade, 0.6 ⁇ g crRNA expression vector (pBS-U6OVATg1-Tg8), 0.6 ⁇ g donor vector corresponding to the crRNA expression vector (pBS- Donor1-Donor8) was suspended in 300 ⁇ l of OPTI-MEM medium (Thermo Fisher Scientific) containing 7 ⁇ l of lipofectamine 2000 and added to cultured primordial germ cells for gene transfer.
  • OPTI-MEM medium Thermo Fisher Scientific
  • neomycin was added to the medium so as to have a final concentration of 0.5 mg / ml, and cells showing drug resistance were selected. After removing neomycin from the medium, the cells were cultured for about 1 month while exchanging the feeder cells and the medium as appropriate, and genomic DNA was recovered from each. Each cell is hereinafter referred to as a primordial germ cell into which Tg1 / Donor1-Tg8 / Donor8 has been introduced.
  • PCR amplification was performed with Takara Mighty Amp 2.0 using 10 ng of genomic DNA as a template and the following primers P1 and P2; Primer P1: acctgtggtgtagacaccagca (SEQ ID NO: 30) Primer P2: aaccgtgcagagaatagactcat (SEQ ID NO: 31).
  • the PCR amplification conditions were 95 ° C. for 2 minutes, followed by 35 cycles of 95 ° C. for 10 seconds, 60 ° C. for 10 seconds, and 72 ° C. for 3 minutes according to the attached manual.
  • the amplified product electrophoresed with 0.8% agarose is shown in the lower left of FIG.
  • An amplification product of expected size of about 3.0 kb was obtained from Tg2 / Donor2 introduced primordial germ cell-derived genomic DNA and from Tg1 / Donor1, Tg3 / Donor3, Tg4 / Donor4 introduced primordial germ cell-derived genomic DNA. Amplification products were also found. On the other hand, almost no amplification product was observed in Tg5 / Donor5-Tg8 / Donor8. From this, it was clarified that by using the combination of Tg2 / Donor2, a foreign gene can be efficiently knocked in to the ovalbumin translation initiation point of chicken primordial germ cells when the CRISPR Cas3 system is used.
  • the region derived from the donor vector and the amplicon amplification efficiency of GAPDH were tested by the StepOnePlus real-time PCR system (Thermo Fisher Scientific) using THUNDERBIRD SYBR qPCR Mix (Toyobo).
  • the reaction conditions were 20 ⁇ l according to Toyobo's manual, and the PCR conditions were 95 ° C. for 2 minutes, followed by 40 cycles of 95 ° C. for 15 seconds and 60 ° C. for 1/2 step cycle.
  • the genomic DNA of the sample is a human GM-CSF heteroknock-in chicken (Ovoalbumin translation) established by the CRISPR / Cas9 method according to the method described in Patent Document 1.
  • a genome derived from (knock-in) at the starting point was used as a control (PC).
  • Ct GAPDH
  • GM-CSF Ct
  • GM-CSF Ct
  • GM-CSF Ct
  • the Tg1 / Donor1, Tg2 / Donor2, Tg3 / Donor3, and Tg4 / Donor4 -introduced primordial germ cell genomes are 1.1%, 54.7%, 6.5%, and 1. It was 0% (lower right graph in Fig. 3). Also, the Tg5 / Donor5-Tg8 / Donor8 introduced primordial germ cell genome did not amplify the distinct donor vector amplicon.
  • Tg2 / Donor2 combination is suitable for knock-in using the CRISPR Cas3 system, and under such conditions, about all alleles of primordial germ cell ovalbumin. It was shown that foreign genes can be knocked in in half. In addition, it was clarified that by using a combination of Tg1 / Donor1, Tg3 / Donor3, and Tg4 / Donor4, a foreign gene can be knocked in to the ovalbumin translation initiation point of chicken primordial germ cells when the CRISPR Cas3 system is used. rice field.
  • a poultry cell knocked in a knock-in method, a method for producing a knocked-in poultry cell, and an egg or poultry containing the knocked-in poultry cell in the egg white protein gene.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2021/022359 2020-06-12 2021-06-11 卵白タンパク質遺伝子における目的タンパク質をコードする遺伝子がノックインされた家禽細胞またはその製造方法 Ceased WO2021251493A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022530639A JPWO2021251493A1 (https=) 2020-06-12 2021-06-11
US18/009,187 US20230257768A1 (en) 2020-06-12 2021-06-11 Poultry cell in which a gene encoding a protein of interest is knocked-in at egg white protein gene, and method for producing said poultry cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-102405 2020-06-12
JP2020102405 2020-06-12

Publications (1)

Publication Number Publication Date
WO2021251493A1 true WO2021251493A1 (ja) 2021-12-16

Family

ID=78846136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/022359 Ceased WO2021251493A1 (ja) 2020-06-12 2021-06-11 卵白タンパク質遺伝子における目的タンパク質をコードする遺伝子がノックインされた家禽細胞またはその製造方法

Country Status (3)

Country Link
US (1) US20230257768A1 (https=)
JP (1) JPWO2021251493A1 (https=)
WO (1) WO2021251493A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114381537A (zh) * 2022-01-27 2022-04-22 深圳瑞德林生物技术有限公司 细菌筛选试剂、筛选方法、试剂盒及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017111144A1 (ja) * 2015-12-25 2017-06-29 国立研究開発法人産業技術総合研究所 遺伝子改変家禽卵
JP2018522530A (ja) * 2015-04-27 2018-08-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系
WO2018225858A1 (ja) * 2017-06-08 2018-12-13 国立大学法人大阪大学 Ｄｎａが編集された真核細胞を製造する方法、および当該方法に用いられるキット
WO2019017321A1 (ja) * 2017-07-18 2019-01-24 国立大学法人京都大学 遺伝子変異導入方法
JP2020510443A (ja) * 2016-12-20 2020-04-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 細胞ゲノムにおける、相同組換え修復（ｈｄｒ）の効率を上昇させるための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091311A1 (en) * 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522530A (ja) * 2015-04-27 2018-08-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系
WO2017111144A1 (ja) * 2015-12-25 2017-06-29 国立研究開発法人産業技術総合研究所 遺伝子改変家禽卵
JP2020510443A (ja) * 2016-12-20 2020-04-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 細胞ゲノムにおける、相同組換え修復（ｈｄｒ）の効率を上昇させるための方法
WO2018225858A1 (ja) * 2017-06-08 2018-12-13 国立大学法人大阪大学 Ｄｎａが編集された真核細胞を製造する方法、および当該方法に用いられるキット
WO2019017321A1 (ja) * 2017-07-18 2019-01-24 国立大学法人京都大学 遺伝子変異導入方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114381537A (zh) * 2022-01-27 2022-04-22 深圳瑞德林生物技术有限公司 细菌筛选试剂、筛选方法、试剂盒及应用
CN114381537B (zh) * 2022-01-27 2024-05-14 深圳瑞德林生物技术有限公司 细菌筛选试剂、筛选方法、试剂盒及应用

Also Published As

Publication number Publication date
US20230257768A1 (en) 2023-08-17
JPWO2021251493A1 (https=) 2021-12-16

Similar Documents

Publication Publication Date Title
JP7731156B2 (ja) Ｄｎａが編集された真核細胞を製造する方法、および当該方法に用いられるキット
JP6700306B2 (ja) 受精前の卵細胞、受精卵、及び標的遺伝子の改変方法
JP2017513510A (ja) ブタにおける多重遺伝子編集
JP6004290B2 (ja) 不活化された内因性遺伝子座を有するトランスジェニックニワトリ
US20190223417A1 (en) Genetically modified animals having increased heat tolerance
US20170223938A1 (en) Transgenic chickens with an inactivated endogenous gene locus
WO2018030208A1 (ja) 遺伝子ノックイン細胞の作製方法
JP2018531003A6 (ja) 向上した耐暑性を有する遺伝子改変動物
JP6923232B2 (ja) 遺伝子改変家禽卵
CN113646429B (zh) 敲入细胞的制作方法
WO2020198541A1 (en) Porcine reproductive and respiratory syndrome virus (prrsv) resistant swine
WO2021251493A1 (ja) 卵白タンパク質遺伝子における目的タンパク質をコードする遺伝子がノックインされた家禽細胞またはその製造方法
CN111849977B (zh) 一种精子载体制备转基因动物的方法以及一种制备矮小型转基因鸡的sgRNA和制备方法
JP2026513245A (ja) ニワトリ胚の性別判定方法
WO2010047423A1 (ja) 変異遺伝子導入方法、変異導入遺伝子、変異導入カセットならびに変異導入ベクターおよびノックイン非ヒト哺乳動物
CN116406383A (zh) FokI核酸酶结构域的突变体
Lucas Toca Edición genómica en ratón basada en la electroporación de CRISPR/Cas9 en cigotos. Aplicación al estudio del síndrome de mano hendida
WO2021171688A1 (ja) 遺伝子ノックイン方法、遺伝子ノックイン細胞作製方法、遺伝子ノックイン細胞、がん化リスク評価方法、がん細胞製造方法、及びこれらに用いるためのキット
CN111073963A (zh) 一种一日龄鉴别鸡受精蛋性别的方法
HK40021189B (zh) Dna被编辑了的真核细胞的制造方法、和在该方法中使用的试剂盒

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21822355

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022530639

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21822355

Country of ref document: EP

Kind code of ref document: A1